RNK08954

To determine the recommended extended dose (RDE) and maximum tolerated dose (MTD) of RNK08954 in subjects with KRAS G12D mutant advanced solid tumors, and to evaluate the safety and tolerability, pharmacokinetic (PK) characteristics, and preliminary evidence of antitumor activity of RNK08954 in subjects with KRAS G12D mutant advanced solid tumors. To further evaluate the safety and tolerability, primary and secondary antitumor efficacy endpoints, and pharmacokinetic (PK) characteristics of RDE dose-treated subjects with KRAS G12D mutant advanced solid tumors. To explore the relationship between safety and/or efficacy endpoints and PK/PD, evaluate PoP PK parameters, explore biomarkers associated with RNK08954, and explore the relationship between changes in biomarkers and efficacy.